Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

(NEXSTAR) – A six-figure income used to be shorthand for “rich.” Now, it’s barely enough to get by in many parts of the country. And it’s not just California and New York where families are feeling ...

In the following table, we look at the core strengths, average undergraduate tuition and fees, and graduation rates for the ...

In total, we have over 400 carefully chosen, rigorously vetted Best in Class picks spanning a dozen categories, from men’s and women’s clothing to sleep gear and tech. So to make them all easy to find ...

The threshold to be considered middle class on average in Colorado is increasing faster than the rest of the country. SmartAsset, an online platform for financial advice and information, once again ...

Your household can earn more than $200,000 a year and still be considered part of the "middle class" in Massachusetts, according to a recent study by SmartAsset. According to a 2022 Gallup survey, ...

[Maximilian Milovidov is a freshman at Columbia University and a member of TikTok's Youth Council. He used a large language model to edit this essay for length and a human to edit for content. This ...

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. In 2025, more than 1,700 class lawsuits were settled for a total of $79 billion—nearly ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.